Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

Delcath to Present at the 28th Annual ROTH Conference

PR Newswire March 7, 2016

Delcath announces Engagement of Lars E. Birgerson, M.D., Ph. D as global medical consultant

PR Newswire February 11, 2016

Delcath Announces Beginning Of Patient Enrollment In Phase 3 Focus Trial

PR Newswire February 10, 2016

Delcath Systems to Present at Upcoming Investor Conferences

PR Newswire February 4, 2016

Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic Dominant Ocular Melanoma

PR Newswire January 20, 2016

MicroCap Review Magazine Winter/Spring 2016 Issue Now Available

Marketwired January 19, 2016

Delcath Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic Dominant Ocular Melanoma

PR Newswire January 19, 2016

Delcath To Present At NobleCon12 Investor Conference

PR Newswire January 15, 2016

Review of Delcath Melphalan/HDS System Published in "Cardiovascular & Interventional Radiology"

PR Newswire January 11, 2016

Delcath Prior Phase 3 Trial Results Published In Annals Of Surgical Oncology

PR Newswire December 9, 2015

Delcath Announces CHEMOSAT Review Accepted for Publication in Cardiovascular and Interventional Radiology

PR Newswire December 8, 2015

Delcath Systems To Host Business Update Conference Call On November 17, 2015

PR Newswire November 11, 2015

Delcath Reports 2015 Third Quarter Financial Results

PR Newswire November 10, 2015

Data Supporting Delcath's CHEMOSAT System Presented At The European Association Of Dermato Oncology Annual Congress

PR Newswire November 2, 2015

Delcath Announces First Patient Treated In ICC Cohort Of Global Phase 2 HCC Trial Program

PR Newswire October 15, 2015

Delcath Phase 3 Trial Results To Be Published In Annals Of Surgical Oncology

PR Newswire October 14, 2015

StockNewsNow.com Publishes New SNNLive Video Interview With Delcath Systems, Inc.

Marketwired October 9, 2015

Delcath Announces National Reimbursement Coverage For CHEMOSAT Procedures In Germany

PR Newswire October 8, 2015

Delcath Systems Appoints CEO Jennifer Simpson To Board Of Directors

PR Newswire October 6, 2015

Data Supporting Delcath's Chemosat System Presented At The Cardiovascular and Interventional Radiology Society Annual Meeting

PR Newswire September 30, 2015